Corticosteroid Use in ARDS

Introduction to Corticosteroid Therapy

The American Thoracic Society suggests using corticosteroids for patients with ARDS (conditional recommendation, moderate certainty of evidence) 1, 2
Pooled analysis of 19 RCTs including 2,790 patients demonstrated that corticosteroids probably decrease mortality (RR 0.84; 95% CI 0.73-0.96; moderate certainty) 3
Corticosteroids may reduce duration of mechanical ventilation (mean difference 4 days less; 95% CI -5.5 to -2.5; low certainty) and length of hospital stay 4

Corticosteroids probably increase the risk of serious hyperglycemia (RR 1.11; 95% CI 1.01-1.23; moderate certainty) based on pooled analysis of multiple trials 4
Close surveillance for adverse effects is essential, particularly in immunocompromised patients, those with metabolic syndrome, or those in regions with endemic tuberculosis 4

Initiating corticosteroids >2 weeks after ARDS onset may be associated with harm 4
The optimal corticosteroid agent, dose, and duration remain unclear due to heterogeneity across trials 4

Dexamethasone 20 mg IV daily for 5 days, then 10 mg IV daily for 5 days was used in DEXA-ARDS, but other regimens (e.g., methylprednisolone) may have advantages 5
Consider methylprednisolone 2 mg/kg/day with slow tapering for late persistent ARDS (after day 6) 5

Monitor blood glucose closely, especially within 36 hours of initiation, and treat hyperglycemia aggressively 5
Continue lung-protective ventilation (tidal volume 6 mL/kg predicted body weight) throughout treatment 5
Assess for gastrointestinal bleeding, neuromuscular weakness, and new infections during therapy 4

The American Thoracic Society conditionally recommends using corticosteroids, including dexamethasone, for patients with ARDS (PaO2/FiO2 <300), as they probably reduce mortality and duration of mechanical ventilation 6, 7, 8

Initiate corticosteroids within the first 14 days of mechanical ventilation; starting after 2 weeks may cause harm 6
Chinese guidelines during COVID-19 recommended methylprednisolone for 3-5 days in severe cases to prevent progression to cytokine storm, emphasizing early intervention 9

Apply corticosteroids to patients meeting these criteria: within 14 days of mechanical ventilation initiation 6
No contraindications (active uncontrolled infection, immunosuppression requiring ongoing therapy) 6

Continue lung-protective ventilation (tidal volume 4-8 mL/kg predicted body weight, plateau pressure <30 cmH2O) throughout corticosteroid treatment 6, 7
Corticosteroids should be used alongside, not instead of, proven ARDS interventions including prone positioning for severe ARDS (PaO2/FiO2 <100) 7, 8
Consider neuromuscular blockade in early severe ARDS as an adjunct to corticosteroid therapy 7, 8

The Society of Critical Care Medicine recommends corticosteroids in patients with early moderate to severe ARDS (PaO₂/FiO₂ <200 within 14 days of onset), as they reduce mortality, shorten mechanical ventilation duration, and improve lung function when initiated early 10, 11
The European Society of Intensive Care Medicine suggests that corticosteroids should be used when the PaO₂/FiO₂ ratio is <200 (moderate to severe ARDS) and within 14 days of ARDS onset 10, 11
Corticosteroid use is associated with a reduction in hospital mortality of 7-11% in patients with mild to severe ARDS 10, 11
The use of corticosteroids reduces mechanical ventilation duration by 4-7 days 10, 11
Early initiation of corticosteroids (<72 hours) is associated with better response to lower doses and faster disease resolution compared to late initiation 10, 11
Prolonged glucocorticoid treatment was not associated with increased risk of nosocomial infection in ARDS trials 10, 12
Two trials reported a significant reduction in risk of developing shock with steroid treatment 10, 12
Hyperglycemia has not been associated with increased morbidity in ARDS trials 10, 12

The optimal window for corticosteroid initiation is <72 hours from ARDS onset for maximum benefit 10, 11
The acceptable window for corticosteroid initiation is up to 14 days from onset 10, 11
Starting therapy >14 days after ARDS onset may increase mortality risk 10, 11

The recommendation is based on moderate quality evidence from the Society of Critical Care Medicine and European Society of Intensive Care Medicine 2017 guidelines 10, 11, 12

The American Thoracic Society recommends the use of corticosteroids in patients with moderate to severe ARDS (PaO₂/FiO₂ <200) when initiated within 14 days of onset, as they reduce mortality and shorten mechanical ventilation duration 13, 14

Initiate corticosteroids in patients with a PaO₂/FiO₂ ratio <200 (moderate to severe ARDS) and within 14 days of ARDS onset, with no active uncontrolled infection 13, 14, 15
Do not initiate corticosteroids if more than 14 days have passed since ARDS onset, as it is associated with harm 13, 14

Methylprednisolone 1 mg/kg/day is the preferred regimen for early disease, showing a better response at lower doses when initiated within 72 hours 15
Methylprednisolone 2 mg/kg/day with slow tapering over 13 days is recommended for late persistent ARDS (Days 7-14) 15

Corticosteroids reduce mortality by 16% relative risk reduction (RR 0.84; 95% CI 0.73-0.96) and shorten mechanical ventilation duration by 4-7 days 13, 14, 15
They also increase ventilator-free days by approximately 4 days and reduce systemic inflammatory cytokines and C-reactive protein 15

Monitor blood glucose closely, especially within the first 36 hours, as corticosteroids increase the risk of serious hyperglycemia 15
Maintain a high index of suspicion for hospital-acquired infections, as glucocorticoids blunt febrile response 15

Use established regimens for severe community-acquired pneumonia and Pneumocystis jirovecii pneumonia in HIV patients 13, 14

The 2024 American Thoracic Society guideline provides a conditional recommendation with moderate certainty of evidence for corticosteroid use 13, 14
The 2017 Society of Critical Care Medicine/European Society of Intensive Care Medicine guideline provides a conditional recommendation with moderate quality evidence specifically for early moderate-to-severe ARDS 15